A Phase 3 study of Tafasitamab plus Lenalidomide in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

You likely can't join if

• 1. Any other histological type of lymphoma according to the WHO 2016 classification of lymphoid neoplasms, including: a. primary mediastinal (thymic) large B-cell lymphoma b. Burkitt lymphoma c. Primary refractory DLBCL, defined as disease progressing in the course of the first line treatment, and/or showing a response of less than a PR to first-line treatment, or disease recurrence/progression within < 6 months from the completion of first-line therapy. d. History of double- or triple-hit DLBCL, characterized by simultaneous detection of MYC with BCL2 and/or BCL6 translocation(s) as per fluorescence in situ hybridization. MYC, BCL2, BCL6 testing prior to study enrollment is not required. 2. History or evidence of CNS lymphoma (primary and secondary). 3. Prior treatment with CD19-targeted therapy or IMiDs (eg, thalidomide, lenalidomide) 4. Participants who, within 30 days prior to Cycle 1 Day 1, have: a. Not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma-specific therapy b. Undergone major surgery or suffered from significant traumatic injury c. Received live vaccines or have an anticipated need for such vaccination while receiving study treatment d. Required parenteral antimicrobial therapy for active, intercurrent infections 5. Have undergone ASCT within the period ≤ 3 months prior to signing consent. If an ASCT was performed > 3 months prior to signing consent, full hematological recovery must be demonstrated before enrollment into the study. Please refer to protocol for a complete list of exclusion criteria.